Scalper1 News
Medical device company Nevro rose 40% in its stock market debut Thursday, and its initial public offering raised $126 million. Nevro (NVRO) develops and markets an implantable spinal cord stimulation system, called Senza, designed to treat chronic pain in the back and legs. In the IPO, Nevro sold 7 million shares, up from 6.25 million originally planned, at 18. That was above the estimated range of 15 to 17. Shares closed at 25.19 in the stock Scalper1 News
Scalper1 News